The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: A real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center.
 
Mark Nalder
No Relationships to Disclose
 
Rahul Ladwa
Honoraria - Ipsen; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche; Sanofi
Travel, Accommodations, Expenses - Ipsen; MSD; Roche; Sanofi; Sun Pharma
 
Anant Raina
No Relationships to Disclose
 
Matthew E. Burge
Stock and Other Ownership Interests - Bristol-Myers Squibb; coclear; CSL Limited; Gilead Sciences; pfizer
Honoraria - Amgen; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Amgen; ipsen; Roche
Research Funding - Amgen (Inst)
Patents, Royalties, Other Intellectual Property - funding for an investigator initiated prospective trial (Inst)
Travel, Accommodations, Expenses - Amgen; Roche; Roche
 
Amanda Love
No Relationships to Disclose
 
David A. Pattison
Consulting or Advisory Role - Telix Pharmaceuticals
Travel, Accommodations, Expenses - Ipsen
 
Stuart Ramsay
No Relationships to Disclose
 
David Wyld
Consulting or Advisory Role - Ipsen; Novartis
Speakers' Bureau - Ipsen
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Novartis